Structure-function-rescue: the diverse nature of common p53 cancer mutants - PubMed (original) (raw)
Review
. 2007 Apr 2;26(15):2226-42.
doi: 10.1038/sj.onc.1210291.
Affiliations
- PMID: 17401432
- DOI: 10.1038/sj.onc.1210291
Review
Structure-function-rescue: the diverse nature of common p53 cancer mutants
A C Joerger et al. Oncogene. 2007.
Abstract
The tumor suppressor protein p53 is inactivated by mutation in about half of all human cancers. Most mutations are located in the DNA-binding domain of the protein. It is, therefore, important to understand the structure of p53 and how it responds to mutation, so as to predict the phenotypic response and cancer prognosis. In this review, we present recent structural and systematic functional data that elucidate the molecular basis of how p53 is inactivated by different types of cancer mutation. Intriguingly, common cancer mutants exhibit a variety of distinct local structural changes, while the overall structural scaffold is largely preserved. The diverse structural and energetic response to mutation determines: (i) the folding state of a particular mutant under physiological conditions; (ii) its affinity for the various p53 target DNA sequences; and (iii) its protein-protein interactions both within the p53 tetramer and with a multitude of regulatory proteins. Further, the structural details of individual mutants provide the basis for the design of specific and generic drugs for cancer therapy purposes. In combination with studies on second-site suppressor mutations, it appears that some mutants are ideal rescue candidates, whereas for others simple pharmacological rescue by small molecule drugs may not be successful.
Similar articles
- Structures of oncogenic, suppressor and rescued p53 core-domain variants: mechanisms of mutant p53 rescue.
Wallentine BD, Wang Y, Tretyachenko-Ladokhina V, Tan M, Senear DF, Luecke H. Wallentine BD, et al. Acta Crystallogr D Biol Crystallogr. 2013 Oct;69(Pt 10):2146-56. doi: 10.1107/S0907444913020830. Epub 2013 Sep 20. Acta Crystallogr D Biol Crystallogr. 2013. PMID: 24100332 Free PMC article. - Structural biology of the tumor suppressor p53 and cancer-associated mutants.
Joerger AC, Fersht AR. Joerger AC, et al. Adv Cancer Res. 2007;97:1-23. doi: 10.1016/S0065-230X(06)97001-8. Adv Cancer Res. 2007. PMID: 17419939 Review. - Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJ, Frolow F, Liran A, Rotter V, Shakked Z. Suad O, et al. J Mol Biol. 2009 Jan 9;385(1):249-65. doi: 10.1016/j.jmb.2008.10.063. Epub 2008 Oct 30. J Mol Biol. 2009. PMID: 18996393 - Structure and Function of p53-DNA Complexes with Inactivation and Rescue Mutations: A Molecular Dynamics Simulation Study.
Kamaraj B, Bogaerts A. Kamaraj B, et al. PLoS One. 2015 Aug 5;10(8):e0134638. doi: 10.1371/journal.pone.0134638. eCollection 2015. PLoS One. 2015. PMID: 26244575 Free PMC article. - How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T, Haran TE. Stiewe T, et al. Drug Resist Updat. 2018 May;38:27-43. doi: 10.1016/j.drup.2018.05.001. Epub 2018 May 9. Drug Resist Updat. 2018. PMID: 29857816 Review.
Cited by
- NOXA as critical mediator for drug combinations in polychemotherapy.
Ehrhardt H, Höfig I, Wachter F, Obexer P, Fulda S, Terziyska N, Jeremias I. Ehrhardt H, et al. Cell Death Dis. 2012 Jun 21;3(6):e327. doi: 10.1038/cddis.2012.53. Cell Death Dis. 2012. PMID: 22717582 Free PMC article. - Intrinsic aggregation propensity of the p63 and p73 TI domains correlates with p53R175H interaction and suggests further significance of aggregation events in the p53 family.
Kehrloesser S, Osterburg C, Tuppi M, Schäfer B, Vousden KH, Dötsch V. Kehrloesser S, et al. Cell Death Differ. 2016 Dec;23(12):1952-1960. doi: 10.1038/cdd.2016.75. Epub 2016 Jul 22. Cell Death Differ. 2016. PMID: 27447112 Free PMC article. - Navigating the complexity of p53-DNA binding: implications for cancer therapy.
Thayer KM, Stetson S, Caballero F, Chiu C, Han ISM. Thayer KM, et al. Biophys Rev. 2024 Jul 11;16(4):479-496. doi: 10.1007/s12551-024-01207-4. eCollection 2024 Aug. Biophys Rev. 2024. PMID: 39309126 Free PMC article. Review. - Pyrimidine Triones as Potential Activators of p53 Mutants.
Fallatah MMJ, Demir Ö, Law F, Lauinger L, Baronio R, Hall L, Bournique E, Srivastava A, Metzen LT, Norman Z, Buisson R, Amaro RE, Kaiser P. Fallatah MMJ, et al. Biomolecules. 2024 Aug 8;14(8):967. doi: 10.3390/biom14080967. Biomolecules. 2024. PMID: 39199355 Free PMC article. - p53-Suppressed Oncogene TET1 Prevents Cellular Aging in Lung Cancer.
Filipczak PT, Leng S, Tellez CS, Do KC, Grimes MJ, Thomas CL, Walton-Filipczak SR, Picchi MA, Belinsky SA. Filipczak PT, et al. Cancer Res. 2019 Apr 15;79(8):1758-1768. doi: 10.1158/0008-5472.CAN-18-1234. Epub 2019 Jan 8. Cancer Res. 2019. PMID: 30622117 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous